Sector News

Perrigo To Acquire Leading OTC Brands From GSK In All-cash Deal

June 3, 2015
Life sciences
(RTTNews) – Perrigo Company plc announced it has entered into an agreement to acquire a portfolio of over-the-counter brands from GlaxoSmithKline Consumer Healthcare, in connection with GSK’s commitments to divest these businesses in the context of the formation of a consumer health joint venture between GSK and Novartis.
 
The assets include: GSK’s NiQuitin nicotine replacement therapy business, primarily in the European Economic Area and Brazil, and Novartis’s legacy Australian NRT business, including the Nicotinell brand; Several assorted OTC brands including Coldrex across the EEA, and Panodil, Nezeril, and Nasin in Sweden; and Novartis’s legacy cold sore management products primarily in the EEA, marketed under the brand names Vectavir, Pencivir, Fenivir, Fenlips and Vectatone.
 
Perrigo expects the acquisition to be immediately accretive to its calendar 2015 adjusted earnings per share, excluding estimated intangible amortization and transaction-related costs. The transaction is expected to close in the third quarter of 2015.

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).